EXLUSIVE REPORT: Psilocybin wonder drugs primed to take the world by storm, enter New Wave Holdings (CSE: SPOR│FWB:0XM2│OTC:TRMND)

By James Moore


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Download our exclusive report to discover how New Wave Holdings

PSILOCYBIN PROMISES TO BECOME AS FAMOUS AS PENICILLIN – Download our exclusive report to discover how New Wave Holdings (CSE: SPORFWB:0XM2OTC:TRMND) is set to dominate this new global market

Psilocybin is one of nature’s miracles.

You might not have heard of it yet, but this little known psychedelic compound promises to do for mental health what penicillin did for antibiotics.

The potential really is that great, and New Wave Holdings (CSE: SPORFWB:0XM2OTC:TRMND) is the one stock that offers maximum exposure to the Psilocybin Revolution.

Found in 200 species of mushroom, psilocybin was first synthesized in 1958 by legendary Swiss chemist Albert Hofmann.

Hofmann made his name 15 years earlier, when he first discovered the effects of LSD. He was the early pioneer of research into psychedelics, and dedicated his life to their investigation following that ground-breaking breakthrough.

What Hofmann foresaw was the incredible potential psychedelic substances had to become the most powerful psychiatric treatments ever invented.

By altering a person’s state of consciousness in a controlled manner, Hofmann was convinced it would be possible to unleash the latent power of the brain to glorious effect.

Hofmann’s vision proved to be far ahead of its time.

By the late 1960’s, political opposition to the recreational use of psychedelics led to global bans.

However, an elite band of scientists remained unperturbed.

Over the next 50 years, they forged ahead with their research, risking the disapproval of society and the scorn of their peers.

Like Hofmann, they recognized the exceptional impact carefully administered microdoses of psilocybin could have on a patient’s wellbeing.

Whether a person terminally ill with cancer or someone suffering from treatment-resistant depression, the evidence is overwhelming that psychedelic medicines can play a hugely beneficial role.

That’s not all.

Products based on psychedelic compounds have even been shown to improve cognitive function, enhance creativity, help regulate sleep patterns and boost general immunity.

Billionaires and other high performers are said to microdose as a way of bringing out their creative best.

And of all the psychedelic compounds, psilocybin has attracted the most intense research focus.


  • Within ten years, multiple approved psilocybin-assisted therapies will enter the global market, and New Wave is perfectly positioned to meet this demand

  • New Wave has set up the world’s first official psilocybin cultivation and extraction centre in Jamaica. Initial production is expected to be 15,200 grams a year, rising to 78,000 grams a year with minimal investment

  • New Wave is positioning itself at the forefront of blockbuster drug development, using psilocybin to treat mental health disorders

  • New Wave is the first listed company to develop and sell medicinal, functional and recreational psychedelic products. The company has already delivered $200,000 in sales with minimal marketing, and has $500,000 of stock inventory ready for immediate sale on full launch

  • The New Wave team is experienced in creating high value companies, having made fortunes in a number of high-profile cannabis exits. This team is using that insight and expertise to launch into this new space with vigour

  • New Wave has also recruited world-class talent in Dr Richard Knowles and Robert Kang to drive its business forward and create research and commercial collaborations

  • New Wave is fully cashed up to deliver its plan, having raised $4 million just two weeks ago with respected investment bank Eight Capital


Paid Advertisement

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by New Wave Holdings Corp to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and forty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

Changes in Share Trading and Price

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

No Offer to Sell or Buy Securities

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy.

No Financial Advice

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

Forward Looking Statements

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

Indemnification/Release of Liability

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

Terms of Use and Disclaimer

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here  https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

Intellectual Property

All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.

Author: Ben Turney

Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

Ben Turney does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. Ben Turney has been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.


In this article:

Author: James Moore

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter